Download PDF
Thromb Haemost 1999; 82(01): 151-152
DOI: 10.1055/s-0037-1614648
Letters to the Editor
Schattauer GmbH

Inhibitor Development in a Multitransfused Patient with Severe Haemophilia A

H. M. van den Berg
1   From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands
,
G. Roosendaal
1   From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands
,
J. Voorberg
2   From the CLB Sanquin Blood Supply Foundation, The Netherlands
,
E.P. Mauser-Bunschoten
1   From the Van Creveld Clinic, University Hospital Utrecht/Wilhelmina Childrens’ Hospital, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 14 January 1998

Accepted 19 February 1999

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao V, Lazerson J. and the Hemophilia Study group. The natural history of factor VIII:C inhibitors in patients with hemophilia: A national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
    PubMedGoogle Scholar
  • 2 Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, Van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
    PubMedGoogle Scholar
  • 3 Rosendaal FR, Nieuwenhuis HK, van den Berg HM. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Blood 1993; 81: 2180-6.
    PubMedGoogle Scholar
  • 4 Peerlinck K, Arnout J, Di Giambattista M. et al. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Sawamoto Y, Prescott R, Zhong D. et al. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors. Tromb Haemost 1998; 79: 62-8.
    PubMedGoogle Scholar